Protagonist Therapeutics, Inc. (PTGX) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Aurinia Pharmaceuticals, Inc.

Geron Corp.

Deciphera Pharmaceuticals, Inc.

Relay Therapeutics, Inc.

Iovance Biotherapeutics, Inc.

Twist Bioscience Corp.

Tango Therapeutics, Inc.

Protagonist Therapeutics, Inc.

Arvinas, Inc.

Disc Medicine, Inc.

Pliant Therapeutics, Inc.

Why is Protagonist Therapeutics, Inc. ?

Poor Management Efficiency with a low ROE of 7.42%

The company has been able to generate a Return on Equity (avg) of 7.42% signifying low profitability per unit of shareholders funds

Flat results in Mar 26

NET SALES(HY) At USD 63.8 MM has Grown at -67.93%
NET PROFIT(HY) At USD -40.6 MM has Grown at -133.83%
OPERATING CASH FLOW(Y) Lowest at USD -116.64 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 109.31%, its profits have fallen by -147.3%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Protagonist Therapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Protagonist Therapeutics, Inc.

109.31%

4.69

51.23%

S&P 500

25.41%

1.92

13.25%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

9.96%

EBIT Growth (5y)

-183.81%

EBIT to Interest (avg)

-33.21

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.83

Sales to Capital Employed (avg)

0.40

Tax Ratio

1.57%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

17.16%

ROE (avg)

7.42%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

10.27

EV to EBIT

-36.36

EV to EBITDA

-36.66

EV to Capital Employed

115.87

EV to Sales

124.96

PEG Ratio

Dividend Yield

ROCE (Latest)

-318.64%

ROE (Latest)

-21.17%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

Bullish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

15What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -0.12% (YoY

CASH AND EQV(HY)

Highest at USD 1,115.15 MM

NET SALES(Q)

Highest at USD 56.37 MM

OPERATING PROFIT(Q)

Highest at USD -3.24 MM

OPERATING PROFIT MARGIN(Q)

Highest at -5.75 %

PRE-TAX PROFIT(Q)

Highest at USD 2.28 MM

NET PROFIT(Q)

Highest at USD 3.78 MM

EPS(Q)

Highest at USD 0.05

-20What is not working for the Company

NET SALES(HY)

At USD 63.8 MM has Grown at -67.93%

NET PROFIT(HY)

At USD -40.6 MM has Grown at -133.83%

OPERATING CASH FLOW(Y)

Lowest at USD -116.64 MM

ROCE(HY)

Lowest at -17.06%

Here's what is working for Protagonist Therapeutics, Inc.

Net Sales

At USD 56.37 MM has Grown at 389.99%

over average net sales of the previous four periods of USD 11.5 MM

MOJO Watch

Near term sales trend is extremely positive

Net Sales (USD MM)

Pre-Tax Profit

At USD 2.28 MM has Grown at 107.06%

over average net sales of the previous four periods of USD -32.33 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit

At USD 3.78 MM has Grown at 111.63%

over average net sales of the previous four periods of USD -32.54 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (USD MM)

Net Sales

Highest at USD 56.37 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Operating Profit

Highest at USD -3.24 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin

Highest at -5.75 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at USD 2.28 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

Highest at USD 3.78 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

EPS

Highest at USD 0.05

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Cash and Eqv

Highest at USD 1,115.15 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost

Fallen by -0.12% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Protagonist Therapeutics, Inc.

Operating Cash Flow

Lowest at USD -116.64 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Non Operating Income

Highest at USD 2.6 MM

in the last five periods

MOJO Watch

Increased income from non business activities may not be sustainable

Non Operating income